EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Bioequivalence Study of Vardenafil Hydrochloride Tablets in Healthy Chinese Subjects

Huan Li, Meixia Hua, Yi Zhang, Lianlian Chen, Bin He, Mei Xu, Tuo Li, Lina Wang, Fangliang Gan, Qisheng Liu

Drugs in R&D · 05.11.2026

DOI: 10.1007/s40268-026-00554-9 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Drugs in R&D, online erschienen am 05.11.2026. Verfasst von Huan Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, 437100, Hubei, China. Hauptthemen laut MEDLINE: Phosphodiesterase 5 Inhibitors, Vardenafil Dihydrochloride. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & OBJECTIVES: Vardenafil hydrochloride, a phosphodiesterase type 5 inhibitor, is used for erectile dysfunction. Bioequivalence testing is required for generic tablet registration in China. The aim of this study was to investigate the bioequivalence of vardenafil hydrochloride tablets in healthy Chinese volunteers under both fasting and fed conditions. METHODS: A single-center, randomized, open-label, two-formulation, single-dose, four-period, fully replicated crossover study was conducted. A total of 24 and 30 healthy subjects were enrolled in the fasting and fed trials, respectively. Venous blood samples were collected in accordance with the study protocol, and plasma concentrations of vardenafil were quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). All data were statistically analyzed using SAS version 9.4, and bioequivalence was subsequently evaluated. RESULTS: Under fasting conditions, the maximum plasma concentrations (Cmax) of the test (T) and reference (R) formulations were 37.10 ± 16.62 ng/mL and 34.76 ± 16.21 ng/mL, respectively; the median (range) times to Cmax (Tmax) were 0.67 h (0.34-1.50) and 0.67 h (0.34-1.00); the areas under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC0-t) were 78.66 ± 44.29 ng·h/mL and 75.61 ± 40.81 ng·h/mL; and the areas under the plasma concentration-time curve from time zero to infinity (AUC0-∞) were 81.44 ± 45.59 ng·h/mL and 78.30 ± 41.51 ng·h/mL. Under fed conditions, the Cmax values of T and R were 25.02 ± 14.54 ng/mL and 26.52 ± 14.23 ng/mL; the Tmax values were 1.34 h (0.25-4.50) and 1.50 h (0.50-5.00); the AUC0-t values were 98.81 ± 47.50 ng·h/mL and 91.20 ± 45.67 ng·h/mL; and the AUC0-∞ values were 101.68 ± 48.28 ng·h/mL and 94.08 ± 46.26 ng·h/mL. The 90% confidence intervals of the geometric mean ratios for the primary pharmacokinetic parameters, including Cmax, AUC0-t, and AUC0-∞, between the test and reference formulations fell entirely within the predefined bioequivalence acceptance range of 80.00-125.00% under both fasting and fed conditions. CONCLUSIONS: The test and reference formulations of vardenafil hydrochloride are bioequivalent with respect to both the rate and extent of absorption after oral administration in healthy Chinese subjects under fasting and fed conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase 5 InhibitorsVardenafil DihydrochlorideAdultHumansMaleYoung AdultAdministration, OralArea Under CurveChinaChromatography, LiquidCross-Over StudiesFastingHealthy VolunteersTabletsTandem Mass SpectrometryTherapeutic EquivalencyEast Asian People

Substanzen

Phosphodiesterase 5 InhibitorsTabletsVardenafil Dihydrochloride

Autor:innen und Institutionen

  • School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, 437100, Hubei, China.
  • Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, 437000, Hubei, China.
  • School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, 437100, Hubei, China. ganfang9876@163.com.
  • Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, 437000, Hubei, China. ganfang9876@163.com.
  • School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, 437100, Hubei, China. 15872070606@hbust.edu.cn.
  • Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, 437000, Hubei, China. 15872070606@hbust.edu.cn.

Zitieren

APA

Li, H., Hua, M., Zhang, Y., Chen, L., He, B., Xu, M., Li, T., Wang, L., Gan, F., & Liu, Q. (2026). Bioequivalence Study of Vardenafil Hydrochloride Tablets in Healthy Chinese Subjects. Drugs in R&D. https://doi.org/10.1007/s40268-026-00554-9

Vancouver

Li H, Hua M, Zhang Y, Chen L, He B, Xu M, et al. Bioequivalence Study of Vardenafil Hydrochloride Tablets in Healthy Chinese Subjects. Drugs in R&D. 2026. doi:10.1007/s40268-026-00554-9

BibTeX
@article{Li2026,
  author = {Li, Huan and Hua, Meixia and Zhang, Yi and Chen, Lianlian and He, Bin and Xu, Mei and Li, Tuo and Wang, Lina and Gan, Fangliang and Liu, Qisheng},
  title = {Bioequivalence Study of Vardenafil Hydrochloride Tablets in Healthy Chinese Subjects},
  journal = {Drugs in R&D},
  year = {2026},
  doi = {10.1007/s40268-026-00554-9}
}
Kostenlos starten →